Macrocyclic Compounds for Treating Cancer (EP4151641A1)

The EPO published European patent application EP4151641A1 for macrocyclic compounds used in cancer therapy, with the applicant and inventors recorded as Turning Point Therapeutics, Inc. and eight named individuals respectively. IPC classifications indicate the compounds fall within the macrocyclic heterocyclic systems therapeutic class (A61P 35/00), specifically under bridged or fused ring systems (C07D 498/22) and heterocyclyl-substituted 1,4-oxazepines (A61K 31/5383). The patent grants exclusivity across all designated EU member states, preventing third parties from making, using, or selling the claimed compounds without authorization in those territories.

For pharmaceutical and biotechnology companies developing targeted oncology therapies, this patent establishes intellectual property boundaries that should be factored into R&D pipeline planning and freedom-to-operate analyses. Generic or biosimilar developers will need to assess whether alternative compound structures can achieve similar therapeutic effects without infringement. The designated state coverage means the exclusivity extends automatically across all 31 EU/EEA countries listed, requiring any competitor seeking to commercialize similar macrocyclic oncology compounds to navigate these claims.